Modified-release formulation of trimetazidine for exceptional control of angina pectoris: Fact or fiction

American Journal of Cardiovascular Drugs

Volumn 5, Issue 5, 2005, Pages 331-334

  Thadani, Udho ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; NICORANDIL; NIFEDIPINE; NITRIC ACID DERIVATIVE; PROPRANOLOL; RANOLAZINE; TRIMETAZIDINE;

ANGINA PECTORIS; CLINICAL TRIAL; COMORBIDITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; LIFESTYLE; LIPID BLOOD LEVEL; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT;

ANGINA PECTORIS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 24944436687     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200505050-00006     Document Type: Note

References (50)

1. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study: prognosis and survival. Am J Cardiol 1972; 29: 154-63
2. American Heart Association. Heart and stroke statistics: 2004 update. Dallas: American Heart Association, 2003
3. Thadani U. Management of stable angina pectoris. Prog Cardiovasc Dis 1999; 14: 349-8
4. Canadian Cardiovascular Society 1997 consensus conference on the evaluation and management of chronic ischemic heart disease. Can J Cardiol 1998; Vol 14 Suppl. C.: 1c-23c
5. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA/ACP-ASIM guideline update for the management of patients with chronic stable angina: summary and abstract. Circulation 2003; 107: 143-58
6. Thadani U. The pursuit of optimum outcomes in stable angina. Am J Cardiovasc Drugs 2003; Suppl. 1: 11-20
7. Thadani U. Current management of chronic stable angina. J Cardiovasc Therapeut 2004; 9 Suppl. 1: S11-29
8. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of ten year results from randomized trials by the coronary artery bypass graft surgery trialists collaboration. Lancet 1994; 344: 563-70
9. Peduzzi P, Kamina A, Detre K, et al. Twenty-two-year follow-up in the VA cooperative study of coronary artery bypass surgery for stable angina: the VA Coronary Artery Bypass Surgery Cooperative Study Group. Am J Cardiol 1998; 81: 1393-9
10. Hartigan PM, Giacomini JC, Folland ED, et al. Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study): VA Cooperative Studies Program ACME Investigators. Am J Cardiol 1998; 82: 1445-50
11. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-6
12. Henderson RA, et al. Seven-year outcome in the RIATA-2 trial: coronary angio-plasty versus medical therapy. The randomized intervention treatment of angina trial participants. J Am Coll Cardiol 2003; 42: 1167-70
13. King SR. Dilate or defer? View of a skeptic. J Am Coll Cardiol 2003; 42: 1171-2
14. Faxon DP. Bringing reality to drug-coated stents. Circulation 2004; 109: 140-2
15. Doll R, Peto R. Mortality in relation to smoking: 20-years' observations on male British doctors. BMJ 1976; 2 (6051): 1525-36
16. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: SAPAT (Swedish Angina Pectoris Aspirin Trial) Group. Lancet 1992; 340: 1421-5
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
18. Rubins HB, Robins S, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Eng J Med 1999; 341: 410-8
19. Pepine CJ, Rouleau JL, Annis K, et al. Effect of angiotensin converting enzyme inhibitor on transient ischemia: the Quinapril anti-ischemia and symptoms of angina reduction (QUASAR) trial. J Am Coll Cardiol 2003; 42: 2043-59
20. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA 999; 281: 1927-36
21. Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 1994; 8: 625-33
22. Thadani U. Nitrate tolerance, rebound and their clinical relevance in stable angina pectoris, unstable angina and heart failure. Cardiovasc Drugs Ther 1996; 10: 735-42
23. Strauss WE, Parisi AF. Combined use of calcium channel and beta blockers for the treatment of stable angina, rationale, efficacy and adverse events. Ann Intern Med 1988; 109: 570-5
24. Dargie HJ, Ford I, Fox KM, et al. Effects of ischemia and treatment with atenolol, nifedipine SR and their combination on outcomes in patient with chronic stable angina: the TIBET Study Group. Eur Heart J 1996; 17: 104-12
25. Thadani U. Combination therapy. Am Coll Cardiol Curr J Rev 1997; 6: 24-5
26. Knight C, Fox K. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Am J Cardiol 1998; 81: 133-6
27. Dunselman PH, van Kempen LH, Bouwens LH, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 1998; 81: 128-32
28. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron Artery Dis 2002; 13: 427-36
29. Akhras F, Jackson A. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991; 338: 1036-9
30. Tolins M, Weir EK, Chesler E, et al. Maximal drug therapy is not necessarily optimal in chronic angina pectoris. Am Coll Cardiol 1984; 4: 1051-7
31. Kim MC, Kini A, Sharma SK. Refractory angina pectoris. J Am Coll Cardiol 2002; 39: 923-34
32. Thadani U. Patient with disabling angina not amenable to revascularization procedures. In: Theroux P, editor. Acute coronary syndromes: a companion to Braunwald's heart disease. Philadelphia (PA): WB Saunders & Co., 2003: 535-52
33. Thadani U. Recurrent and refractory angina following revascularization procedures in patients with stable angina [editorial]. Coron Artery Dis 2004; 15 Suppl. 1: S1-4
34. Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induces angina: controlled multicenter double blind versus placebo study. Arch Mal Coeur Vaiss 1986; 79: 1331-6
35. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic and long term survival during ranolazine monotherapy in patients with severe chronic stable angina: the monotherapy assessment of ranolazine in stable angina (MARISA) Investi-gators. J Am Coll Cardiol 2004; 43: 1375-82
36. Chaitman BR, Pepine J, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: the CARISA Study Group. JAMA 2004; 291: 309-16
37. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol 1998; 30: A112
38. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8
39. Passeron J. Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency: a double-blind versus placebo study. Presse Med 1986; 15: 1775-8
40. Gallet M. Clinical effectiveness of trimetazidine in stable effort angina: a double-blind versus placebo-controlled study. Presse Med 1986; 15: 1779-82
41. Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina; a double-blind crossover study. Cardiovasc Drugs Ther 1990; 4 Suppl. 4: 853-9
42. Levy S, Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 76: 353-7
43. Michaelides AP, Vyssoulis GP, Bonoris PB. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Therapeut Res 1989; 46: 1179-90
44. Michaelides AP, Spiropoulos K, Dimopoulos K, et al. Anti-anginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997; 13: 8-14
45. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol. Eur Heart J 2001; 22: 2267-74
46. Genissel P, Chodjania Y, Demolis JL, et al. Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. Eur J Drug Metab Pharmaco 2004; 29: 61-8
47. Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 2003; 3 (5): 361-9
48. Gupta R, Sawhney JPS, Narain VS. Treatment of stable angina with trimetazidine modified release in Indian primary care. Am J Cardiovasc Drugs 2005; 5 (5): 333-7
49. Leon MB, Bain DS, Moses JW, et al. Direct laser myocardial revascularization with Biosense™ LV electromechanical mapping in patients with refractory myocardial ischemia: final results of a blind randomized clinical trial. JACC 2001; 38: 595-6
50. Stone GSW, Teirstein PS, Rubenstein R, et al. A prospective, multicenter, randomized trial of percutaneous laser revascularization in patients with non-recanaliz-able ostial occlusions. J Am Coll Cardiol 2002; 39 (10): 1581-7